InnoCare Pharma Limited provided earnings guidance for the year ended December 31, 2021. For the period, the group expects to record a consolidated net loss of not more than approximately RMB 100 million as compared with a consolidated net loss of approximately RMB 464 million for the same period in 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.3 HKD | +0.70% | -8.90% | -37.59% |
05-16 | InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis | CI |
05-14 | Innocare Pharma Posts Q1 Loss | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.59% | 1.09B | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021